{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.8"},{"groupId":"OG001","value":"92.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"570"},{"groupId":"OG001","value":"640"}],"units":"Participants"}],"description":"An AE is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants with 1 or more AEs was assessed.","groups":[{"description":"Young adult women 16- to 26-years old received V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.","id":"OG000","title":"Women 16-26 Years of Age"},{"description":"Adult women 27- to 45-years old received V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.","id":"OG001","title":"Women 27-45 Years of Age"}],"paramType":"NUMBER","populationDescription":"All participants that received at least 1 vaccination and had available data for endpoint.","reportingStatus":"POSTED","timeFrame":"Up to 1 month post vaccination 3 (up to 7 months)","title":"Percentage of Participants That Experienced at Least 1 Adverse Event (AE)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}